-
1
-
-
77949351406
-
Drug interactions evaluation: an integrated part of risk assessment of therapeutics
-
Zhang L,Reynolds KS,Zhao P,Huang SM.Drug interactions evaluation: an integrated part of risk assessment of therapeutics.Toxicol Appl Pharmacol. 2010;243:134-145.
-
(2010)
Toxicol Appl Pharmacol
, vol.243
, pp. 134-145
-
-
Zhang, L.1
Reynolds, K.S.2
Zhao, P.3
Huang, S.M.4
-
2
-
-
84892488819
-
Regulatory and scientific aspects of drug-drug interaction studies
-
Greenblatt DJ.Regulatory and scientific aspects of drug-drug interaction studies.Clin Pharmacol Drug Dev. 2012;1:43-44.
-
(2012)
Clin Pharmacol Drug Dev
, vol.1
, pp. 43-44
-
-
Greenblatt, D.J.1
-
3
-
-
0034004083
-
Effects of the antifungal agents on oxidative drug metabolism in humans: clinical relevance
-
Venkatakrishnan K,von Moltke LL,Greenblatt DJ.Effects of the antifungal agents on oxidative drug metabolism in humans: clinical relevance.Clin Pharmacokinet. 2000;38:111-180.
-
(2000)
Clin Pharmacokinet
, vol.38
, pp. 111-180
-
-
Venkatakrishnan, K.1
von Moltke, L.L.2
Greenblatt, D.J.3
-
4
-
-
70849085550
-
Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase
-
Greenblatt DJ,Peters DE,Oleson LE, et al.Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase.Br J Clin Pharmacol. 2009;68:920-927.
-
(2009)
Br J Clin Pharmacol
, vol.68
, pp. 920-927
-
-
Greenblatt, D.J.1
Peters, D.E.2
Oleson, L.E.3
-
5
-
-
13144257695
-
Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences
-
Greenblatt DJ,von Moltke LL,Harmatz JS, et al.Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences.Clin Pharmacol Ther. 1998;64:278-285.
-
(1998)
Clin Pharmacol Ther
, vol.64
, pp. 278-285
-
-
Greenblatt, D.J.1
von Moltke, L.L.2
Harmatz, J.S.3
-
6
-
-
0029130840
-
Macrolide antibacterials: drug interactions of clinical significance
-
von Rosensteil NA,Adam D.Macrolide antibacterials: drug interactions of clinical significance.Drug Safety. 1995;13:105-122.
-
(1995)
Drug Safety
, vol.13
, pp. 105-122
-
-
von Rosensteil, N.A.1
Adam, D.2
-
8
-
-
0033770638
-
Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin
-
Westphal JF.Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin.Br J Clin Pharmacol. 2000;50:285-295.
-
(2000)
Br J Clin Pharmacol
, vol.50
, pp. 285-295
-
-
Westphal, J.F.1
-
9
-
-
0030077245
-
Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole
-
von Moltke LL,Greenblatt DJ,Harmatz JS, et al.Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole.J Pharmacol Exp Ther. 1996;276:370-379.
-
(1996)
J Pharmacol Exp Ther
, vol.276
, pp. 370-379
-
-
von Moltke, L.L.1
Greenblatt, D.J.2
Harmatz, J.S.3
-
10
-
-
13144307073
-
Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences
-
Greenblatt DJ,Wright CE,von Moltke LL, et al.Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences.Clin Pharmacol Ther. 1998;64:237-247.
-
(1998)
Clin Pharmacol Ther
, vol.64
, pp. 237-247
-
-
Greenblatt, D.J.1
Wright, C.E.2
von Moltke, L.L.3
-
11
-
-
63849243096
-
Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm
-
Stoch SA,Friedman E,Maes A, et al.Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm.J Clin Pharmacol. 2009;49:398-406.
-
(2009)
J Clin Pharmacol
, vol.49
, pp. 398-406
-
-
Stoch, S.A.1
Friedman, E.2
Maes, A.3
-
12
-
-
0023571651
-
The pharmacokinetics of ketoconazole after chronic administration in adults
-
Badcock NR,Bartholomeusz FD,Frewin DB,Sansom LN,Reid JG.The pharmacokinetics of ketoconazole after chronic administration in adults.Eur J Clin Pharmacol. 1987;33:531-534.
-
(1987)
Eur J Clin Pharmacol
, vol.33
, pp. 531-534
-
-
Badcock, N.R.1
Bartholomeusz, F.D.2
Frewin, D.B.3
Sansom, L.N.4
Reid, J.G.5
-
15
-
-
36549059303
-
Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring
-
Zhou SF,Xue CC,Yu XQ,Li C,Wang G.Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring.Ther Drug Monit. 2007;29:687-710.
-
(2007)
Ther Drug Monit
, vol.29
, pp. 687-710
-
-
Zhou, S.F.1
Xue, C.C.2
Yu, X.Q.3
Li, C.4
Wang, G.5
-
16
-
-
45249121177
-
Drugs behave as substrates, inhibitors and inducers of human Cytochrome P450 3A4
-
Zhou SF.Drugs behave as substrates, inhibitors and inducers of human Cytochrome P450 3A4.Curr Drug Metab. 2008;9:310-322.
-
(2008)
Curr Drug Metab
, vol.9
, pp. 310-322
-
-
Zhou, S.F.1
-
17
-
-
33644827609
-
Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human Cytochrome P4503A substrate
-
Polasek TM,Miners JO.Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human Cytochrome P4503A substrate.Eur J Clin Pharmacol. 2006;62:203-208.
-
(2006)
Eur J Clin Pharmacol
, vol.62
, pp. 203-208
-
-
Polasek, T.M.1
Miners, J.O.2
-
18
-
-
24944510505
-
Cytochrome P450 enzymes mechanism based inhibitors: common sub-structures and reactivity
-
Fontana E,Dansette PM,Poli SM.Cytochrome P450 enzymes mechanism based inhibitors: common sub-structures and reactivity.Curr Drug Metab. 2005;6:413-454.
-
(2005)
Curr Drug Metab
, vol.6
, pp. 413-454
-
-
Fontana, E.1
Dansette, P.M.2
Poli, S.M.3
-
19
-
-
34548738229
-
Drug-drug interactions via mechanism-based Cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation
-
Venkatakrishnan K,Obach RS.Drug-drug interactions via mechanism-based Cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation.Curr Drug Metab. 2007;8:449-462.
-
(2007)
Curr Drug Metab
, vol.8
, pp. 449-462
-
-
Venkatakrishnan, K.1
Obach, R.S.2
-
20
-
-
34548049514
-
Effect of the treatment period with erythromycin on Cytochrome P450 3A activity in humans
-
Okudaira T,Kotegawa T,Imai H,Tsutsumi K,Nakano S,Ohashi K.Effect of the treatment period with erythromycin on Cytochrome P450 3A activity in humans.J Clin Pharmacol. 2007;47:871-876.
-
(2007)
J Clin Pharmacol
, vol.47
, pp. 871-876
-
-
Okudaira, T.1
Kotegawa, T.2
Imai, H.3
Tsutsumi, K.4
Nakano, S.5
Ohashi, K.6
|